European Commission Approves Uplizna for Generalized Myasthenia Gravis
European Commission has approved Amgen's Uplizna (inebilizumab) as an adjunctive treatment for generalized myasthenia gravis across EU markets. Amgen's senior vice president Jean-Charles Soria will present pipeline developments at Citi’s Virtual Oncology Leadership Summit via webcast on Feb. 18.
1. EC Approval of Uplizna
The European Commission approved Uplizna (inebilizumab) as adjunctive therapy for generalized myasthenia gravis across all EU member states, expanding Amgen’s neuromuscular disease portfolio and marking its first inebilizumab indication.
2. Market and Revenue Outlook
Uplizna’s EU approval opens access to thousands of generalized myasthenia gravis patients, potentially supporting midterm revenue growth and enhancing Amgen’s position in rare disease immunology.
3. Upcoming Oncology Leadership Summit Presentation
Jean-Charles Soria, Amgen’s senior vice president of oncology global development, will present key pipeline updates at Citi’s Virtual Oncology Leadership Summit on Feb. 18 at 12:15 p.m. PT, with a live webcast and 90-day replay via Amgen’s Investor Relations site.